SlideShare a Scribd company logo
1 of 36
Cardiomiopatia prin
non-compactare
Medic rezident: Druleac Larisa
Coordonator: Dr. Erimescu Constantin
D.A., sex F, 71 ani, mediu urban
Factori de risc cardiovasculari
● Varsta
● Hipertensiune arteriala
● Diabet zaharat tip II
● Dislipidemie
● Fumatoare
Antecedente heredo-colaterale-
nesemnificative
● dispnee inspiratorie
● fatigabilitate la efort de intensitate
moderata
● in 29.06.2021- pacienta prezinta un
episod de edem pulmonar acut
remis medicamentos la Spitalul
Municipal de Urgenta Timisoara
Motivele Internarii
● Hipertensiune arteriale esentiala gradul
III cu risc cardiovascular foarte inalt
● Diabet zaharat tip II trata cu ADO
● Dislipidemie sub tratament
● Insuficienta cardiaca NYHA II
● Aspenter 75 mg 0-1-0
● Sortis 40 mg 0-0-1
● Diurex 20/50 mg 1-0-0
● Betaloc Zok 50 mg 1-0-0
● Entresto 24/26 mg 1-0-1
● Glucofage 750 mg 0-0-1
ANTECENDENTE PERSONALE
PATOLOGICE
MEDICATIA DE FOND
● stare generala relativ buna
● IMC=29,4 kg/m2
Aparat cardiovascular:
● Zgomote cardiace ritmice, fara sufluri cardiace si carotidiene audibile,
● TAdr=125/75 mmHg, TAst=120/80 mmHg
● FC=75 bpm
● Pulsuri periferice prezente bilateral
● Fara edeme la nivelul membrelor inferior
Aparat respirator :
● torace normal conformat
● murmur vezicular prezent bilateral
● fara raluri supraadaugate
● SpO2=96% spontan
EXAMEN OBIECTIV
Ritm sinusal, ax QRS deviat
la stanga, QRS fragmentat in
DIII, AVF, subdenivelare
segment ST de 2 mm in
DI,DII,AVL, subdenivelare
segment ST orizontal
descendenta de 2,5 mm in
V4-V6 si unde T negative in
V4-V6.
ECG LA INTERNARE
Ritm sinusal pe toata durata inregistrarii, FC min=60 b-min. Fcmax=100 b-min, fara episoade de fibrilatie atriala ,
fara episoade de tahicardie ventriculara nesustinuta sau sustinuta, fara pause sinusale >3000msec
MONITORIZARE HOLTER ECG
Valori patologice
● Vsh 40 mm/h
● NT-proBNP=215pg/ml
● BNP= 1000pg/ml
Valori normale
● Hemoleucograma4,33 x106
● Hematocrit 38,5 %
● Hemoglobina 13,1 g/dl
● Neutrofile 5,78 ori 103
● Trombocite 221 ori 103
● NA 137 mmol/l
● K 4 mmol/l
● CK 93 u/l U/L
● CK MB 14 UL
● TROPONINA 18,4 ng/ml
Biologic
● Glicemie 103 mg/dl
● Colesterol 128 mg/dl
● Trigliceride 73 mg/dl
● Ldl-c 74 mg/dl
● Creatinina 0,66 mg/dll
● Acid uric 3,8 mg/dl
● LDH 418 U/L
● AST 27 U/L
● ALT 25 U/L
ECOGRAFIA TRANSTORACICA
● Parasternal ax lung
● Ao asc.=4,1 cm VD=2,4 cm
● AS=4,7 cm DTDVS=6,5 cm
● SIV=1,2 cm
● Apical 2C, 3C, 4C
● VTD=215 ml VTD=249 ml
● VTS=168 ml VTS=168 ml
● FEVS=26% biplan
● VolAS=75 ml
● Supraf, AS=23 cm2
● E=0,34 m/s, A=0, 76 m/s, E’Siv=0,02
m/s, A’Siv=0,06 m/s, S’Siv=0,03 m/s
● Vmax tricuspida=2,1 m/s, Pmax
tricuspida=18 mmHG
● TAPSE=1,5 cm
● Anevrism sept interatrial
● Regurgitare mitrala mixta, degenerativa si
prin dilatare de inel mitral, gradul II/III
● Regurgitare tricuspidiana functionala
gradul II
● Regurgitare aortica generativa gradul II
● Regurgitare pulmonara functionala gradul
I
● Trabeculatii bine repezentate la nivelul
apex VS, perete lateral, inferior, anterior
si posterior
● NC/C>2-conform Criteriului Jenni
ECOCARDIOGRAFIA TRANSTORACICA
Soliman OI, McGhie J, ten Cate
FJ, Paelinck BP. Multimodality
imaging, diagnostic challenges
and proposed diagnostic
algorithm for noncompaction
cardiomyopathy.
Angiocoronarografie
Ghid ESC 2021
Ghid ESC 2015
● Artere coronare fara
leziuni vizibile
angiocoronarografic
● Artere carotide fara
leziuni vizile
angiografic.
Ghid ESC 2021
CRITERIILE RMN PENTRU DIAGNOSTICUL DE
CARDIOMIOPATIE PRIN NON-COMPACTARE
• Petersen : NC/C >2,3 la
finalul diastolei
• Stacey :NC/C >2 la finalul
sistolei
• Jacquier-pentru a aprecia masa
de non-compatare a ventriculului
NC/C myocardial mass*100%
>20% .
Prevalence and Prognostic Significance of Left
Ventricular Noncompaction in Patients Referred for
Cardiac Magnetic Resonance Imaging
ESTE NECESAR IMPLANTUL UNUI DEFIBRILATOR?
Sub protectie antibiotica s-a realizat implantul
unui defibrilator cardiac unicameral
Medtronic intern programat in modul VVI cu
fereastra pentru FV=200 bpm si TV=167 bpm
RX TORACE POST IMPLANT DEFIBRILAOR
ESTE NECESAR ANTICOAGULAREA?
Anevrism de sept interatrial
DIAGNOSTIC LA EXTERNARE
• Cardiomiopatie dilatativa prin
non-compactare
• Insuficienta cardiaca NYHA III
cu fractie de ejectie scazuta
• Hipertensiune arteriala esentiala
gradul III risc cardiovascular
foarte inalt
• Regurgiatre mitrala mixta,
degenerativa si prin dilatare de
inel, gradul III
• Regurgitare tricuspidiana
functionala gradul II
• Regurgitare aortica
degenerativa gradul II
• Regurgitare pulmonara
functionala gradul I
• Anevrism sept interatrial
• Diabet zaharat tip II tratat cu
ADO
• Dislipidemie sub tratament
● Entresto 24/26 mg 1-0-1
● Forxiga 10 mg 1-0-0
● Betaloc Zok 50 mg 1-0-1
● Sortis 20 mg 0-0-1
● Diurex 20/50 mg 1-0-0
● Aspenter 75 mg 0-1-0
● Eliquis 5 mg 1/2-0-1/2
● Glucophage 750 mg 0-0-1
TRATAMENT
LA EXTERNARE
Nu exista indicatii clare in ceea ce priveste implantul unui
defibrilator cardiac la pacientii cu cardiomiopatie prin
non-compactare si conduita tratamentului anticoagulant
PARTICULARITATEA CAZULUI
MULTUMESC!

More Related Content

Featured

PEPSICO Presentation to CAGNY Conference Feb 2024
PEPSICO Presentation to CAGNY Conference Feb 2024PEPSICO Presentation to CAGNY Conference Feb 2024
PEPSICO Presentation to CAGNY Conference Feb 2024Neil Kimberley
 
Content Methodology: A Best Practices Report (Webinar)
Content Methodology: A Best Practices Report (Webinar)Content Methodology: A Best Practices Report (Webinar)
Content Methodology: A Best Practices Report (Webinar)contently
 
How to Prepare For a Successful Job Search for 2024
How to Prepare For a Successful Job Search for 2024How to Prepare For a Successful Job Search for 2024
How to Prepare For a Successful Job Search for 2024Albert Qian
 
Social Media Marketing Trends 2024 // The Global Indie Insights
Social Media Marketing Trends 2024 // The Global Indie InsightsSocial Media Marketing Trends 2024 // The Global Indie Insights
Social Media Marketing Trends 2024 // The Global Indie InsightsKurio // The Social Media Age(ncy)
 
Trends In Paid Search: Navigating The Digital Landscape In 2024
Trends In Paid Search: Navigating The Digital Landscape In 2024Trends In Paid Search: Navigating The Digital Landscape In 2024
Trends In Paid Search: Navigating The Digital Landscape In 2024Search Engine Journal
 
5 Public speaking tips from TED - Visualized summary
5 Public speaking tips from TED - Visualized summary5 Public speaking tips from TED - Visualized summary
5 Public speaking tips from TED - Visualized summarySpeakerHub
 
ChatGPT and the Future of Work - Clark Boyd
ChatGPT and the Future of Work - Clark Boyd ChatGPT and the Future of Work - Clark Boyd
ChatGPT and the Future of Work - Clark Boyd Clark Boyd
 
Getting into the tech field. what next
Getting into the tech field. what next Getting into the tech field. what next
Getting into the tech field. what next Tessa Mero
 
Google's Just Not That Into You: Understanding Core Updates & Search Intent
Google's Just Not That Into You: Understanding Core Updates & Search IntentGoogle's Just Not That Into You: Understanding Core Updates & Search Intent
Google's Just Not That Into You: Understanding Core Updates & Search IntentLily Ray
 
Time Management & Productivity - Best Practices
Time Management & Productivity -  Best PracticesTime Management & Productivity -  Best Practices
Time Management & Productivity - Best PracticesVit Horky
 
The six step guide to practical project management
The six step guide to practical project managementThe six step guide to practical project management
The six step guide to practical project managementMindGenius
 
Beginners Guide to TikTok for Search - Rachel Pearson - We are Tilt __ Bright...
Beginners Guide to TikTok for Search - Rachel Pearson - We are Tilt __ Bright...Beginners Guide to TikTok for Search - Rachel Pearson - We are Tilt __ Bright...
Beginners Guide to TikTok for Search - Rachel Pearson - We are Tilt __ Bright...RachelPearson36
 
Unlocking the Power of ChatGPT and AI in Testing - A Real-World Look, present...
Unlocking the Power of ChatGPT and AI in Testing - A Real-World Look, present...Unlocking the Power of ChatGPT and AI in Testing - A Real-World Look, present...
Unlocking the Power of ChatGPT and AI in Testing - A Real-World Look, present...Applitools
 
12 Ways to Increase Your Influence at Work
12 Ways to Increase Your Influence at Work12 Ways to Increase Your Influence at Work
12 Ways to Increase Your Influence at WorkGetSmarter
 
Ride the Storm: Navigating Through Unstable Periods / Katerina Rudko (Belka G...
Ride the Storm: Navigating Through Unstable Periods / Katerina Rudko (Belka G...Ride the Storm: Navigating Through Unstable Periods / Katerina Rudko (Belka G...
Ride the Storm: Navigating Through Unstable Periods / Katerina Rudko (Belka G...DevGAMM Conference
 
Barbie - Brand Strategy Presentation
Barbie - Brand Strategy PresentationBarbie - Brand Strategy Presentation
Barbie - Brand Strategy PresentationErica Santiago
 

Featured (20)

PEPSICO Presentation to CAGNY Conference Feb 2024
PEPSICO Presentation to CAGNY Conference Feb 2024PEPSICO Presentation to CAGNY Conference Feb 2024
PEPSICO Presentation to CAGNY Conference Feb 2024
 
Content Methodology: A Best Practices Report (Webinar)
Content Methodology: A Best Practices Report (Webinar)Content Methodology: A Best Practices Report (Webinar)
Content Methodology: A Best Practices Report (Webinar)
 
How to Prepare For a Successful Job Search for 2024
How to Prepare For a Successful Job Search for 2024How to Prepare For a Successful Job Search for 2024
How to Prepare For a Successful Job Search for 2024
 
Social Media Marketing Trends 2024 // The Global Indie Insights
Social Media Marketing Trends 2024 // The Global Indie InsightsSocial Media Marketing Trends 2024 // The Global Indie Insights
Social Media Marketing Trends 2024 // The Global Indie Insights
 
Trends In Paid Search: Navigating The Digital Landscape In 2024
Trends In Paid Search: Navigating The Digital Landscape In 2024Trends In Paid Search: Navigating The Digital Landscape In 2024
Trends In Paid Search: Navigating The Digital Landscape In 2024
 
5 Public speaking tips from TED - Visualized summary
5 Public speaking tips from TED - Visualized summary5 Public speaking tips from TED - Visualized summary
5 Public speaking tips from TED - Visualized summary
 
ChatGPT and the Future of Work - Clark Boyd
ChatGPT and the Future of Work - Clark Boyd ChatGPT and the Future of Work - Clark Boyd
ChatGPT and the Future of Work - Clark Boyd
 
Getting into the tech field. what next
Getting into the tech field. what next Getting into the tech field. what next
Getting into the tech field. what next
 
Google's Just Not That Into You: Understanding Core Updates & Search Intent
Google's Just Not That Into You: Understanding Core Updates & Search IntentGoogle's Just Not That Into You: Understanding Core Updates & Search Intent
Google's Just Not That Into You: Understanding Core Updates & Search Intent
 
How to have difficult conversations
How to have difficult conversations How to have difficult conversations
How to have difficult conversations
 
Introduction to Data Science
Introduction to Data ScienceIntroduction to Data Science
Introduction to Data Science
 
Time Management & Productivity - Best Practices
Time Management & Productivity -  Best PracticesTime Management & Productivity -  Best Practices
Time Management & Productivity - Best Practices
 
The six step guide to practical project management
The six step guide to practical project managementThe six step guide to practical project management
The six step guide to practical project management
 
Beginners Guide to TikTok for Search - Rachel Pearson - We are Tilt __ Bright...
Beginners Guide to TikTok for Search - Rachel Pearson - We are Tilt __ Bright...Beginners Guide to TikTok for Search - Rachel Pearson - We are Tilt __ Bright...
Beginners Guide to TikTok for Search - Rachel Pearson - We are Tilt __ Bright...
 
Unlocking the Power of ChatGPT and AI in Testing - A Real-World Look, present...
Unlocking the Power of ChatGPT and AI in Testing - A Real-World Look, present...Unlocking the Power of ChatGPT and AI in Testing - A Real-World Look, present...
Unlocking the Power of ChatGPT and AI in Testing - A Real-World Look, present...
 
12 Ways to Increase Your Influence at Work
12 Ways to Increase Your Influence at Work12 Ways to Increase Your Influence at Work
12 Ways to Increase Your Influence at Work
 
ChatGPT webinar slides
ChatGPT webinar slidesChatGPT webinar slides
ChatGPT webinar slides
 
More than Just Lines on a Map: Best Practices for U.S Bike Routes
More than Just Lines on a Map: Best Practices for U.S Bike RoutesMore than Just Lines on a Map: Best Practices for U.S Bike Routes
More than Just Lines on a Map: Best Practices for U.S Bike Routes
 
Ride the Storm: Navigating Through Unstable Periods / Katerina Rudko (Belka G...
Ride the Storm: Navigating Through Unstable Periods / Katerina Rudko (Belka G...Ride the Storm: Navigating Through Unstable Periods / Katerina Rudko (Belka G...
Ride the Storm: Navigating Through Unstable Periods / Katerina Rudko (Belka G...
 
Barbie - Brand Strategy Presentation
Barbie - Brand Strategy PresentationBarbie - Brand Strategy Presentation
Barbie - Brand Strategy Presentation
 

Prezentare

  • 1. Cardiomiopatia prin non-compactare Medic rezident: Druleac Larisa Coordonator: Dr. Erimescu Constantin
  • 2. D.A., sex F, 71 ani, mediu urban Factori de risc cardiovasculari ● Varsta ● Hipertensiune arteriala ● Diabet zaharat tip II ● Dislipidemie ● Fumatoare Antecedente heredo-colaterale- nesemnificative
  • 3. ● dispnee inspiratorie ● fatigabilitate la efort de intensitate moderata ● in 29.06.2021- pacienta prezinta un episod de edem pulmonar acut remis medicamentos la Spitalul Municipal de Urgenta Timisoara Motivele Internarii
  • 4. ● Hipertensiune arteriale esentiala gradul III cu risc cardiovascular foarte inalt ● Diabet zaharat tip II trata cu ADO ● Dislipidemie sub tratament ● Insuficienta cardiaca NYHA II ● Aspenter 75 mg 0-1-0 ● Sortis 40 mg 0-0-1 ● Diurex 20/50 mg 1-0-0 ● Betaloc Zok 50 mg 1-0-0 ● Entresto 24/26 mg 1-0-1 ● Glucofage 750 mg 0-0-1 ANTECENDENTE PERSONALE PATOLOGICE MEDICATIA DE FOND
  • 5. ● stare generala relativ buna ● IMC=29,4 kg/m2 Aparat cardiovascular: ● Zgomote cardiace ritmice, fara sufluri cardiace si carotidiene audibile, ● TAdr=125/75 mmHg, TAst=120/80 mmHg ● FC=75 bpm ● Pulsuri periferice prezente bilateral ● Fara edeme la nivelul membrelor inferior Aparat respirator : ● torace normal conformat ● murmur vezicular prezent bilateral ● fara raluri supraadaugate ● SpO2=96% spontan EXAMEN OBIECTIV
  • 6. Ritm sinusal, ax QRS deviat la stanga, QRS fragmentat in DIII, AVF, subdenivelare segment ST de 2 mm in DI,DII,AVL, subdenivelare segment ST orizontal descendenta de 2,5 mm in V4-V6 si unde T negative in V4-V6. ECG LA INTERNARE
  • 7. Ritm sinusal pe toata durata inregistrarii, FC min=60 b-min. Fcmax=100 b-min, fara episoade de fibrilatie atriala , fara episoade de tahicardie ventriculara nesustinuta sau sustinuta, fara pause sinusale >3000msec MONITORIZARE HOLTER ECG
  • 8. Valori patologice ● Vsh 40 mm/h ● NT-proBNP=215pg/ml ● BNP= 1000pg/ml Valori normale ● Hemoleucograma4,33 x106 ● Hematocrit 38,5 % ● Hemoglobina 13,1 g/dl ● Neutrofile 5,78 ori 103 ● Trombocite 221 ori 103 ● NA 137 mmol/l ● K 4 mmol/l ● CK 93 u/l U/L ● CK MB 14 UL ● TROPONINA 18,4 ng/ml Biologic ● Glicemie 103 mg/dl ● Colesterol 128 mg/dl ● Trigliceride 73 mg/dl ● Ldl-c 74 mg/dl ● Creatinina 0,66 mg/dll ● Acid uric 3,8 mg/dl ● LDH 418 U/L ● AST 27 U/L ● ALT 25 U/L
  • 10.
  • 11.
  • 12.
  • 13. ● Parasternal ax lung ● Ao asc.=4,1 cm VD=2,4 cm ● AS=4,7 cm DTDVS=6,5 cm ● SIV=1,2 cm ● Apical 2C, 3C, 4C ● VTD=215 ml VTD=249 ml ● VTS=168 ml VTS=168 ml ● FEVS=26% biplan ● VolAS=75 ml ● Supraf, AS=23 cm2 ● E=0,34 m/s, A=0, 76 m/s, E’Siv=0,02 m/s, A’Siv=0,06 m/s, S’Siv=0,03 m/s ● Vmax tricuspida=2,1 m/s, Pmax tricuspida=18 mmHG ● TAPSE=1,5 cm ● Anevrism sept interatrial ● Regurgitare mitrala mixta, degenerativa si prin dilatare de inel mitral, gradul II/III ● Regurgitare tricuspidiana functionala gradul II ● Regurgitare aortica generativa gradul II ● Regurgitare pulmonara functionala gradul I ● Trabeculatii bine repezentate la nivelul apex VS, perete lateral, inferior, anterior si posterior ● NC/C>2-conform Criteriului Jenni ECOCARDIOGRAFIA TRANSTORACICA
  • 14.
  • 15. Soliman OI, McGhie J, ten Cate FJ, Paelinck BP. Multimodality imaging, diagnostic challenges and proposed diagnostic algorithm for noncompaction cardiomyopathy.
  • 17. ● Artere coronare fara leziuni vizibile angiocoronarografic ● Artere carotide fara leziuni vizile angiografic.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23. CRITERIILE RMN PENTRU DIAGNOSTICUL DE CARDIOMIOPATIE PRIN NON-COMPACTARE • Petersen : NC/C >2,3 la finalul diastolei • Stacey :NC/C >2 la finalul sistolei • Jacquier-pentru a aprecia masa de non-compatare a ventriculului NC/C myocardial mass*100% >20% . Prevalence and Prognostic Significance of Left Ventricular Noncompaction in Patients Referred for Cardiac Magnetic Resonance Imaging
  • 24. ESTE NECESAR IMPLANTUL UNUI DEFIBRILATOR?
  • 25.
  • 26.
  • 27.
  • 28.
  • 29. Sub protectie antibiotica s-a realizat implantul unui defibrilator cardiac unicameral Medtronic intern programat in modul VVI cu fereastra pentru FV=200 bpm si TV=167 bpm
  • 30. RX TORACE POST IMPLANT DEFIBRILAOR
  • 32. Anevrism de sept interatrial
  • 33. DIAGNOSTIC LA EXTERNARE • Cardiomiopatie dilatativa prin non-compactare • Insuficienta cardiaca NYHA III cu fractie de ejectie scazuta • Hipertensiune arteriala esentiala gradul III risc cardiovascular foarte inalt • Regurgiatre mitrala mixta, degenerativa si prin dilatare de inel, gradul III • Regurgitare tricuspidiana functionala gradul II • Regurgitare aortica degenerativa gradul II • Regurgitare pulmonara functionala gradul I • Anevrism sept interatrial • Diabet zaharat tip II tratat cu ADO • Dislipidemie sub tratament
  • 34. ● Entresto 24/26 mg 1-0-1 ● Forxiga 10 mg 1-0-0 ● Betaloc Zok 50 mg 1-0-1 ● Sortis 20 mg 0-0-1 ● Diurex 20/50 mg 1-0-0 ● Aspenter 75 mg 0-1-0 ● Eliquis 5 mg 1/2-0-1/2 ● Glucophage 750 mg 0-0-1 TRATAMENT LA EXTERNARE
  • 35. Nu exista indicatii clare in ceea ce priveste implantul unui defibrilator cardiac la pacientii cu cardiomiopatie prin non-compactare si conduita tratamentului anticoagulant PARTICULARITATEA CAZULUI